FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313236671> ?p ?o ?g. }

• W4313236671 endingPage "544" @default.
• W4313236671 startingPage "535" @default.
• W4313236671 abstract "Study aims were to analyze prospectively collected data from patients with cancer-associated venous thromboembolism (VTE) to determine the impact of VTE recurrence and anticoagulant-related bleeding on all-cause mortality. Consecutive cancer patients with acute VTE treated with anticoagulants (March 1, 2013-November 30, 2021) were included in this analysis. Anticoagulant therapy-associated VTE recurrences, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were assessed for their impact on all-cause mortality outcomes. This study included 1,812 cancer patients with VTE. Of these, there were 97 (5.4%) with recurrent VTE, 98 (5.4%) with major, and 104 (5.7%) with CRNMB while receiving anticoagulants. Recurrent VTE (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.16-2.00; p = 0.0028), major bleeding (HR: 1.82; 95% CI: 1.41-2.31; p = 0.006), and CRNMB (HR; 1.38; 95% CI: 1.05-1.81; p = 0.018) each adversely influenced mortality outcomes. Deep vein thrombosis as the incident thrombotic event type was associated with VTE recurrence (HR: 1.78; 95% CI: 1.08-2.89; p = 0.02). Neither cancer type nor stage, chemotherapy, or Ottawa risk category influenced VTE recurrence. Higher body weights (HR: 1.01; 95% CI: 1.00-1.01; p = 0.005) were associated with increased major bleeding, while high Ottawa scores (HR: 0.66; 95% CI: 0.46-0.96; p = 0.03) and apixaban treatment (HR: 0.62; 95% CI: 0.45-0.84; p = 0.002) were associated with fewer major bleeding outcomes. Among cancer patients receiving anticoagulant therapy for VTE, adverse outcomes such as VTE recurrence, major bleeding, or CRNMB increase mortality risk by 40 to 80%. Identifying variables predicting these outcomes may help risk-stratify patients with poor prognosis." @default.
• W4313236671 created "2023-01-06" @default.
• W4313236671 creator A5017032740 @default.
• W4313236671 creator A5018306647 @default.
• W4313236671 creator A5026536861 @default.
• W4313236671 creator A5050586204 @default.
• W4313236671 creator A5060027910 @default.
• W4313236671 creator A5060617809 @default.
• W4313236671 creator A5079076674 @default.
• W4313236671 creator A5086294602 @default.
• W4313236671 creator A5089993641 @default.
• W4313236671 date "2022-12-27" @default.
• W4313236671 modified "2023-09-30" @default.
• W4313236671 title "Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment" @default.
• W4313236671 cites W1634950970 @default.
• W4313236671 cites W1964644585 @default.
• W4313236671 cites W1975259121 @default.
• W4313236671 cites W1978080273 @default.
• W4313236671 cites W1984833612 @default.
• W4313236671 cites W2010481138 @default.
• W4313236671 cites W2010745882 @default.
• W4313236671 cites W2018856451 @default.
• W4313236671 cites W2032094474 @default.
• W4313236671 cites W2043211308 @default.
• W4313236671 cites W2054324054 @default.
• W4313236671 cites W2076621544 @default.
• W4313236671 cites W2127599046 @default.
• W4313236671 cites W2138438886 @default.
• W4313236671 cites W2162398328 @default.
• W4313236671 cites W2162499932 @default.
• W4313236671 cites W2281570169 @default.
• W4313236671 cites W2332736166 @default.
• W4313236671 cites W2775434460 @default.
• W4313236671 cites W2802130786 @default.
• W4313236671 cites W2885394836 @default.
• W4313236671 cites W2943255556 @default.
• W4313236671 cites W2981274404 @default.
• W4313236671 cites W3013809005 @default.
• W4313236671 cites W3104890556 @default.
• W4313236671 cites W3194200408 @default.
• W4313236671 cites W3197407971 @default.
• W4313236671 doi "https://doi.org/10.1055/s-0042-1758835" @default.
• W4313236671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36574777" @default.
• W4313236671 hasPublicationYear "2022" @default.
• W4313236671 type Work @default.
• W4313236671 citedByCount "5" @default.
• W4313236671 countsByYear W43132366712023 @default.
• W4313236671 crossrefType "journal-article" @default.
• W4313236671 hasAuthorship W4313236671A5017032740 @default.
• W4313236671 hasAuthorship W4313236671A5018306647 @default.
• W4313236671 hasAuthorship W4313236671A5026536861 @default.
• W4313236671 hasAuthorship W4313236671A5050586204 @default.
• W4313236671 hasAuthorship W4313236671A5060027910 @default.
• W4313236671 hasAuthorship W4313236671A5060617809 @default.
• W4313236671 hasAuthorship W4313236671A5079076674 @default.
• W4313236671 hasAuthorship W4313236671A5086294602 @default.
• W4313236671 hasAuthorship W4313236671A5089993641 @default.
• W4313236671 hasConcept C121608353 @default.
• W4313236671 hasConcept C126322002 @default.
• W4313236671 hasConcept C141071460 @default.
• W4313236671 hasConcept C207103383 @default.
• W4313236671 hasConcept C2776301958 @default.
• W4313236671 hasConcept C2778205648 @default.
• W4313236671 hasConcept C2778661090 @default.
• W4313236671 hasConcept C2778959117 @default.
• W4313236671 hasConcept C2779161974 @default.
• W4313236671 hasConcept C2780011451 @default.
• W4313236671 hasConcept C2780638905 @default.
• W4313236671 hasConcept C2780868729 @default.
• W4313236671 hasConcept C2781362458 @default.
• W4313236671 hasConcept C2991741193 @default.
• W4313236671 hasConcept C44249647 @default.
• W4313236671 hasConcept C71924100 @default.
• W4313236671 hasConcept C90924648 @default.
• W4313236671 hasConceptScore W4313236671C121608353 @default.
• W4313236671 hasConceptScore W4313236671C126322002 @default.
• W4313236671 hasConceptScore W4313236671C141071460 @default.
• W4313236671 hasConceptScore W4313236671C207103383 @default.
• W4313236671 hasConceptScore W4313236671C2776301958 @default.
• W4313236671 hasConceptScore W4313236671C2778205648 @default.
• W4313236671 hasConceptScore W4313236671C2778661090 @default.
• W4313236671 hasConceptScore W4313236671C2778959117 @default.
• W4313236671 hasConceptScore W4313236671C2779161974 @default.
• W4313236671 hasConceptScore W4313236671C2780011451 @default.
• W4313236671 hasConceptScore W4313236671C2780638905 @default.
• W4313236671 hasConceptScore W4313236671C2780868729 @default.
• W4313236671 hasConceptScore W4313236671C2781362458 @default.
• W4313236671 hasConceptScore W4313236671C2991741193 @default.
• W4313236671 hasConceptScore W4313236671C44249647 @default.
• W4313236671 hasConceptScore W4313236671C71924100 @default.
• W4313236671 hasConceptScore W4313236671C90924648 @default.
• W4313236671 hasIssue "05" @default.
• W4313236671 hasLocation W43132366711 @default.
• W4313236671 hasLocation W43132366712 @default.
• W4313236671 hasOpenAccess W4313236671 @default.
• W4313236671 hasPrimaryLocation W43132366711 @default.
• W4313236671 hasRelatedWork W2058317838 @default.
• W4313236671 hasRelatedWork W2399439482 @default.

• next